Description of Local Modifications of Lymph Nodes or Bundles With the FABIR Sequence in MRIALTREVENCT05041569
Description of Lymphatic Damage in Encephalic Venous Thrombosis and Strictures in MRI a Reverse-recovery Sequence: a Pilot Study
An observational study of Description of Local Modifications of Lymph Nodes or Bundles With the FABIR Sequence in MRI, run by Fondation Ophtalmologique Adolphe de Rothschild at 1 site in France.
Trial summary
Inclusion (J0): Information Verification of inclusion and non-inclusion criteria Collection of consent MRI examination with injection of contrast product as part of the treatment comprising the sequences: T1 TFE 1.0 iso 3D FLAIR injected Injected elliptical venous angiography 0.4mm iso or less 3D SWIp multiecho 3D T1… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Description of Local Modifications of Lymph Nodes or Bundles With the FABIR Sequence in MRI
- What is being tested?
- MRI sequences
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 17 Dec 2021to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient presenting for imaging as part of their treatment
Who may be able to join
- Patients over 18 years of age
- Performing an MRI injected as part of care for one of the following reasons:
- suspicion of pathology likely to be associated with narrowing or obstruction of one or more venous sinuses (cerebral thrombophlebitis, tissue damage with venous extension, idiopathic HIC
- venous narrowing or obstruction proven by one of the above pathologies, requiring as part of routine care an injected MRI (search for impact, monitoring, pre-therapeutic assessment or prognosis)
- Express consent to participate in the study
- Affiliate or beneficiary of a social security scheme
Who cannot join
- Absolute contraindication to MRI
- Patient benefiting from a legal protection measure
- Pregnant or breastfeeding woman
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Hhopital fondation adolphe de rothschild
Paris, Paris, 75019
Amelie ya, 0148036454, ayavchitz@for.paris
julien savatovsky
About this study
Inclusion (J0):
- Information
- Verification of inclusion and non-inclusion criteria
- Collection of consent
- MRI examination with injection of contrast product as part of the treatment comprising the sequences:
Read more
T1 TFE 1.0 iso 3D FLAIR injected Injected elliptical venous angiography 0.4mm iso or less 3D SWIp multiecho 3D T1 injected FABIR iso without injection (added as part of care in case of suspected ASH or meningitis) FLAIR 1.0 without injection (added as part of care for suspected ASH or meningitis) T2 BFFE XD (added by search) FABIR iso injected (added by research) 3D PD T1 0.55 MSDE iso injected (added by research)
Clinical information (SRM on inclusion, on discharge and at 3 months and recurrence within the year) will be collected from the patient's medical file
- Conditions
- Description of Local Modifications of Lymph Nodes or Bundles With the FABIR Sequence in MRI
- Being tested
- MRI sequences
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRI sequencesOther
perform additional sequences added by research
What is being measured
The primary outcome is the main question the study is designed to answer.
Using a new MRI sequence for the detection of lymph nods
Inversion recovery pulse sequences in MRI will be used to detect lymph nods.
Measured: 1 DAY
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Sep 2021
- Study start17 Dec 2021
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Description of Local Modifications of Lymph Nodes or Bundles With the FABIR Sequence in MRIStudies of the same condition, open and under way.
- More trials run by Fondation Ophtalmologique Adolphe de RothschildThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Sponsor type
- Research network
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05041569
- Sponsor's protocol ID
- JSY_2021_12
- Acronym
- ALTREVE
- Status last verified
- Feb 2026
- First submitted
- 15 Jul 2021
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Description of Lymphatic Damage in Encephalic Venous Thrombosis and Strictures in MRI a Reverse-recovery Sequence: a Pilot Study
- ClinicalTrials.gov ID
- NCT05041569
- Acronym / sponsor ID
- ALTREVE / JSY_2021_12
- Conditions
- Description of Local Modifications of Lymph Nodes or Bundles With the FABIR Sequence in MRI
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Fondation Ophtalmologique Adolphe de RothschildResearch network
- Study start
- 17 Dec 2021 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 13 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Inclusion (J0):
- Information
- Verification of inclusion and non-inclusion criteria
- Collection of consent
- MRI examination with injection of contrast product as part of the treatment comprising the sequences:
T1 TFE 1.0 iso 3D FLAIR injected Injected elliptical venous angiography 0.4mm iso or less 3D SWIp multiecho 3D T1 injected FABIR iso without injection (added as part of care in case of suspected ASH or meningitis) FLAIR 1.0 without injection (added as part of care for suspected ASH or meningitis) T2 BFFE XD (added by search) FABIR iso injected (added by research) 3D PD T1 0.55 MSDE iso injected (added by research)
Clinical information (SRM on inclusion, on discharge and at 3 months and recurrence within the year) will be collected from the patient's medical file
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient presenting for imaging as part of their treatment
Key inclusion criteria (6 listed)
- Patients over 18 years of age
- Performing an MRI injected as part of care for one of the following reasons:
- suspicion of pathology likely to be associated with narrowing or obstruction of one or more venous sinuses (cerebral thrombophlebitis, tissue damage with venous extension, idiopathic HIC
- venous narrowing or obstruction proven by one of the above pathologies, requiring as part of routine care an injected MRI (search for impact, monitoring, pre-therapeutic assessment or prognosis)
- Express consent to participate in the study
Key exclusion criteria (3 listed)
- Absolute contraindication to MRI
- Patient benefiting from a legal protection measure
- Pregnant or breastfeeding woman
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRI sequencesperform additional sequences added by research | Other | – |
Primary outcome
Using a new MRI sequence for the detection of lymph nods
Time frame: 1 DAY
Inversion recovery pulse sequences in MRI will be used to detect lymph nods.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Description of Local Modifications of Lymph Nodes or Bundles With the FABIR Sequence in MRI, run by Fondation Ophtalmologique Adolphe de Rothschild at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact amélie YAVCHITZ (0148036454, ayavchitz@for.paris), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Using a new MRI sequence for the detection of lymph nods (time frame: 1 DAY). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.